



**Key Indices Update** 

| •        | •         |            |
|----------|-----------|------------|
| Indices  | Close     | Change (%) |
| Nifty    | 24,574.20 | لا31.0     |
| Sensex   | 80,543.99 | لاا0.21    |
| Midcap   | 56,749.75 | ∠08.0      |
| Smallcap | 17,662.60 | 1.132      |

#### Trend Strength Indicator

| Nifty 50 Stocks above | NSE Advance / |
|-----------------------|---------------|
| 200 EMA               | Decline       |
| 28                    | 844/2127      |

#### **Key Data**

| Data                     | Current  | Previous |
|--------------------------|----------|----------|
| Dow Jones                | 44,275.9 | 44,175.9 |
| U.S. Dollar Index        | 98.29    | 98.82    |
| Brent Crude (USD/BBL)    | 67.44    | 67.94    |
| US 10Y Bond Yield (%)    | 4.25     | 4.22     |
| India 10Y Bond Yield (%) | 6.37     | 6.37     |

#### Sectoral Data

| Sector     | Close    | Change (%)   |
|------------|----------|--------------|
| BANKNIFTY  | 55481.65 | 0.227        |
| NIFTYAUTO  | 23763.40 | 0.47צ        |
| NIFTYENERG | 34723.50 | لا55.0       |
| NIFTYFINSR | 28383.70 | لا0.03<br>لا |
| NIFTYFMCG  | 55321.10 | 0.74ע        |
| NIFTYIT    | 34517.80 | ו.47צ        |
| NIFTYMEDIA | 1626.25  | لا0.84       |
| NIFTYMETAL | 9320.60  | ע1.17        |
| NIFTYPHARM | 21598.60 | וב 1.69      |
| NIFTYREALT | 895.20   | الـ 1.39     |

Aug 07, **2025** 

#### **Fundamental**

Refer Page 02

#### Stock for Investment

| Stock Name | Sector    | *CMP (₹) | ^TP (₹) | Upside |
|------------|-----------|----------|---------|--------|
| RELINACE   | Oil & Gas | 1,393    | 1,600   | 14.9%  |

\*CMP as on August 06 2025

#### **Top News**

- + Infosys opened a new center in Hubballi, India, focused on AI, Cybersecurity, and Space Technology. The center, part of the 'Infosys Living Labs' network, aims to accelerate innovation for clients globally. It employs over 1,000 people and fosters collaboration with local institutions. This expansion highlights Infosys's commitment to regional growth & creating jobs.
- + RITES Ltd announced its Q1 FY26 results. Revenue from operations stood at ₹455.73 Cr, with a net profit of ₹66.65 Cr. The company declared a 1st interim dividend of ₹1.30 per share. The record date for the dividend is August 12, 2025.

## **Technical**

Refer Page 03-04

- + Nifty remained volatile on Wednesday and ended lower amid mixed cues.
- + After a flat start, the **Nifty oscillated within a range and** eventually settled near the lower end at 24,574.20.
- + The recent price action reflects indecisiveness among market participants amid ongoing uncertainty surrounding tariffs and trade deals.
- + Any negative surprise on this front could exert further pressure, with the **next support for the Nifty placed at 24,450.**
- + On the upside, the 24,700-24,800 zone may continue to act as an immediate hurdle.
- + Participants should align their positions accordingly, with a emphasis on stock selection and risk management.
- + Stock of the day M&M





# **Fundamental**

## Top News

01

Bajaj Holdings & Investment's Q1 FY25 results were announced. The company reported a profit after tax of ₹2,035.74 Cr and a total comprehensive income of ₹2,636.00 Cr.

- 02
- RITES Ltd announced its Q1 FY26 results. Revenue from operations stood at ₹455.73 Cr, with a net profit of ₹66.65 Cr. The company declared a 1st interim dividend of ₹1.30 per share. The record date for the dividend is August 12, 2025.
- 03
- Hawkins Cookers announced unaudited financial results for the quarter ended June 30, 2025. Revenue from operations was ₹239.08 Cr. Net profit after tax stood at ₹25.94 Cr.
- 04
- Infosys opened a new center in Hubballi, India, focused on AI, Cybersecurity, and Space Technology. The center, part of the 'Infosys Living Labs' network, aims to accelerate innovation for clients globally. It employs over 1,000 people and fosters collaboration with local institutions. This expansion highlights Infosys's commitment to regional growth & creating jobs.
- 05

Godrej Agrovet announced its Q1 FY26 results. Revenue from operations increased to ₹2,614.29 Cr from ₹2,350.75 Cr YoY. Profit before tax stood at ₹218.67 Cr, up from ₹182.73 Cr YoY. The company's subsidiary, Astec LifeSciences, has also approved a rights issue of ₹249.35 Cr.

#### Stock for Investment

## **Reliance Industries Ltd**

| Stock Symbol  | RELIANCE  |
|---|-----------|
| Sector  | Oil & Gas |
| *CMP (₹)  | 1,393     |
| ^Target Price<br>(₹)                                      | 1,600     |
| Upside  | 14.9%     |
| *CMP as on August 06, 2025 ^Time horizon - upto 11 Months |           |
| Time nonzon apto il Montino                               |           |

- Reliance Industries is a diversified conglomerate with leading positions in Oil to Chemicals (O2C), Oil & Gas, Retail, Telecom, Media, and a rapidly emerging New Energy business.
- + Jio continues its strong momentum with healthy subscriber additions (9.9 million in Q1) and steady ARPU growth, driven by deeper 5G penetration. Future growth is expected from ongoing premiumization initiatives, which should further support ARPU and margin expansion.
- + The retail segment demonstrated robust growth and improving efficiency, with margins expanding due to cost controls. Rapid expansion in the FMCG business, strong growth in JioMart's quick commerce, and renewed store additions are set to drive improvements in revenue and EBITDA per square foot.
- + While the O2C business benefited from strong fuel cracks, the media segment emerged as a significant growth driver, led by the successful monetization of the IPL. The New Energy giga-factories are nearing operational status (within 4-6 quarters), positioning the business as a key long-term value creator.
- + Based on this strong quarterly performance and future outlook, we forecast Revenue/EBITDA to grow at a CAGR of 10%/15.1% over FY25-27E. We change our rating to "Accumulate" with a target price of ₹1,600.





# **Technical**

## Facing pressure on rise. Maintain caution.

| NIFTY                    |  |
|--------------------------|--|
| 24574.20 🛂 75.35 (0.31%) |  |

| S1    | <b>S2</b> | R1    | R2    |
|-------|-----------|-------|-------|
| 24450 | 24200     | 24700 | 24820 |



- + Nifty remained volatile on Wednesday and ended lower amid mixed cues.
- + After a flat start, the Nifty oscillated within a range and eventually settled near the lower end at 24,574.20.
- Any negative surprise on this front could exert further pressure, with the next support for the Nifty placed at 24,450.
- + On the upside, the 24,700-24,800 zone may continue to act as an immediate hurdle.
- + Participants should align their positions accordingly, with a emphasis on stock selection and risk management.

|   | BANKNIFTY                       |  |
|---|---------------------------------|--|
| į | 55411.15 <b>7</b> 50.90 (0.09%) |  |

| S1    | <b>S2</b> | R1    | R2    |
|-------|-----------|-------|-------|
| 54900 | 54500     | 55800 | 56200 |

#### Technical Chart : **Daily**



- The Banking Index traded sideways initially but gained strength in the latter half, closing with a slight positive bias.
- + While forming higher highs and higher lows intraday, it remains below the 21-day and 50-day EMAs.
- Most constituents ended in the green, except AU Small Finance Bank, IndusInd Bank, and IDFC First Bank, which showed weakness.
- Immediate support lies at 54,900-54,500, while resistance is expected near 56,000-56,200, aligned with key short-term moving averages.





### **Technical**

| Stock of the day | Recom. | CMP (₹) | Range*    | SL   | Target |
|------------------|--------|---------|-----------|------|--------|
| м&м              | BUY    | 3227.50 | 3220-3230 | 3120 | 3425   |



- M&M is approaching its all-time high, upheld by a robust ascending trendline that signals continued short-term bullish momentum.
- The price action demonstrates a higher high and higher low pattern, confirming an uptrend, with key support from the 21- and 50-period EMAs.
- Weekly charts reveal an inverse head-and-shoulders pattern, currently approaching the neckline, suggesting a potential strong upside breakout.
- Investors may consider initiating long positions at recommended entry levels.

| Name      | Price   | Price % |
|-----------|---------|---------|
| SAREGAMA  | 498.00  | 3.587   |
| EPL       | 226.00  | 3.047   |
| RAYMOND   | 645.65  | 2.35⊅   |
| EIDPARRY  | 1209.90 | 1.207   |
| ELGIEQUIP | 555.05  | 2.95كا  |

| Nume      | FIICE   | FIICE 76 | _          |
|-----------|---------|----------|------------|
| BRITANNIA | 5400.50 | 4.17ש    | kang<br>Br |
| COFORGE   | 1639.20 | 3.96ك    | reak       |
| PGEL      | 760.65  | 3.82ك    | down       |
| PPLPHARMA | 186.94  | ו 3.41   | ) OL       |
| ZYDUSLIFE | 936.95  | 2.43ك    |            |
|           |         |          |            |

| Gainers A | Name       | Price   | Price % |
|-----------|------------|---------|---------|
|           | IIFL       | 452.50  | 3.467   |
|           | UNIONBANK  | 131.05  | 2.407   |
| Top 5 F&O | TIINDIA    | 2971.00 | 2.387   |
|           | BLUESTARCO | 1786.30 | 2.037   |
|           | ASIANPAINT | 2484.10 | 1.947   |

| Price    | Price %                                 | Тор   |
|----------|---|---|
| 38170.00 | ב-5.97                                  | បា  |
| 751.70   | 4.96كا                                  | F&O   |
| 6026.00  | 4.73ك                                   |   |
| 553.10   | 4.46كا                                  | Losers  |
| 5390.00  | 4.36كا                                  | K   |
|          | 38170.00<br>751.70<br>6026.00<br>553.10 | 38170.00 5.97 3<br>751.70 4.96 3<br>6026.00 4.73 3<br>553.10 4.46 3 |

| ırts    | Name       | Price   | Price % |
|---------|------------|---------|---------|
|         | ASIANPAINT | 2484.10 | 1.947   |
| Charts  | ABFRL      | 76.30   | 1.507   |
| Bullish | HDFCLIFE   | 752.40  | 1.887   |
|         | INDIGO     | 5871.00 | 1.557   |
|         | PIDILITIND | 3042.00 | 1.487   |
|         |            |         |         |

| Name      | Price   | Price % | _       |
|-----------|---------|---------|---------|
| COFORGE   | 1635.00 | 4.20كا  | Bearish |
| CONCOR    | 553.10  | 4.46ك   |         |
| DIVISLAB  | 6183.00 | 3.532   | Charts  |
| PPLPHARMA | 186.50  | 3.63ك   | rts     |
| SYNGENE   | 672.00  | 3.70كا  |         |





# **Research Team**

| Name              | Email ID                       |
|-------------------|--------------------------------|
| Ajit Mishra       | ajit.mishra@religare.com       |
| Abhijeet Banerjee | abhijeet.banerjee@religare.com |
| Gaurav Sharma     | gauravsharma2@religare.com     |
| Ashwani Harit     | ashwani.harit@religare.com     |
| Divya Parmar      | divya.parmar@religare.com      |
| Vinay Kalani      | vinay.kalani1@religare.com     |
| Rajan Gupta       | rajan.gupta1@religare.com      |





# **Disclaimer**

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <a href="https://www.religareonline.com/disclaimer">https://www.religareonline.com/disclaimer</a>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation—Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

| S.<br>No. | Statement   |     | Answer |  |
|-----------|---|-----|--------|--|
|           |   | Yes | No     |  |
|           | I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]  |     | No     |  |
|           | I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance? |     | No     |  |
|           | I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?  |     | No     |  |
|           | I/we have received any compensation from the subject company in the past twelve months?   |     | No     |  |
|           | I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?  |     | No     |  |
|           | I/we have received any compensation for brokerage services from the subject company in the past twelve months?  |     | No     |  |
|           | I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?  |     | No     |  |
|           | I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?   |     | No     |  |
|           | I/we have served as an officer, director or employee of the subject company?  |     | No     |  |
|           | I/we have been engaged in market making activity for the subject company?   |     | No     |  |

| Nature of Interest if answer to F(a) above is Yes: | Name(s) with Signature(s) of RA(s) |
|--|------------------------------------|

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

| SS. No. | Name(s) of RA. | Signatures of RA | Serial Question of question which the signing RA needs to make a separate declaration / answer | Yes | No |
|---------|----------------|------------------|--|-----|----|
|         |                |                  |  |     |    |
|         |                |                  |  |     |    |

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results







